NCT04537468Source recordAI-normalized
Development of a Method to Measure mRNA Levels From the Skin of Patients With Psoriasis and Patients With Atopic Dermatitis Using Tape Strippings
Innovaderm Research Inc.'s study focuses on developing a non-invasive method to measure mRNA levels in skin samples, which could enhance diagnostic capabilities and therapeutic monitoring for psoriasis and atopic dermatitis. The potential commercialization of this method could position Innovaderm favorably in the dermatology market, particularly as non-invasive diagnostic tools gain traction. The study's completion may attract interest from pharmaceutical companies seeking to integrate biomarker assessments into their clinical trials, thereby enhancing the value proposition of their dermatological products. Competitive implications include the need to monitor similar technologies and methodologies being developed by other entities in the dermatology space.
AI analysis
Indication: Healthy
Modality: RNA therapy
Target: mRNA levels in skin samples from patients with psoriasis and atopic dermatitis
Sponsor: Innovaderm Research Inc.
Source URL: ClinicalTrials.gov
Source updated: Sep 04, 2020
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Healthy, Atopic Dermatitis Eczema, Psoriasis
Condition normalized: Healthy, Atopic Dermatitis Eczema, Psoriasis
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: mRNA levels in skin samples from patients with psoriasis and atopic dermatitis
Target normalized: mRNA levels in skin samples from patients with psoriasis and atopic dermatitis
NCT06729645Source recordAI-normalized
ACO/ARO/AIO-22 - External Beam Radiotherapy Combined With Endorectal High-dose-ratebrachytherapy in Elderly and Frail Patients With Rectal Cancer. A Prospective Multicentre Trial of the German Rectal Cancer Study Group
ACO/ARO/AIO-22 - External beam radiotherapy combined with endorectal high-dose-ratebrachytherapy in elderly and frail patients with rectal cancer. A prospective multicentre trial of the German Rectal Cancer Study Group.
AI analysis
Indication: Rectal Cancer
Modality: RNA therapy
Target: radiotherapy
Sponsor: University Hospital of Cologne
Source URL: ClinicalTrials.gov
Source updated: May 01, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Rectal Cancer
Condition normalized: Rectal Cancer
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: radiotherapy
Target normalized: radiotherapy
NCT03392896Source recordAI-normalized
A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)
This is a double-blind, placebo-controlled, dose escalation trial of DCR-PHXC in Healthy Volunteers (HVs) and patients with Primary Hyperoxaluria (PH). Once safety has been established in HV, PH patients with a confirmed diagnosis of PH1 and PH2 will be enrolled across multiple dosing cohorts. The study design will allow enrollment of PH patient cohorts at a given dose level once safety has been demonstrated in HV at that dose level. The study will be conducted in two parts: Part A: Single ascending dose (SAD) in HV; Part B: SAD in patients with PH1 and PH2 (lagging Part A by 1 dose level cohort).
AI analysis
Indication: Primary Hyperoxaluria
Modality: RNA therapy
Target: DCR-PHXC, Placebo
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Source URL: ClinicalTrials.gov
Source updated: Sep 19, 2024
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Primary Hyperoxaluria
Condition normalized: Primary Hyperoxaluria
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: DCR-PHXC, Placebo
Target normalized: DCR-PHXC, Placebo
NCT05537571Source recordAI-normalized
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events
AI analysis
Indication: Cardiovascular Diseases
Modality: RNA therapy
Target: SLN360, Placebo
Sponsor: Silence Therapeutics plc
Source URL: ClinicalTrials.gov
Source updated: Jul 01, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)
Condition normalized: Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: SLN360, Placebo
Target normalized: SLN360, Placebo
NCT03029312Source recordAI-normalized
Whole Body Vibration as an Osteogenic Treatment for Children With Osteogenesis Imperfecta With Limited Mobility: A Randomised Controlled Pilot Trial
Children with osteogenesis imperfecta (OI) have impaired bone strength, fractures, weak muscles and limited mobility. Mild to moderate forms of OI (type 1 and 4) may benefit from muscle training that leads to secondary improvement in bone strength (osteogenic treatment). Recent studies in children with cerebral palsy but also OI suggest that Whole Body Vibration Training (WBVT) improves mobility and also bone strength. No randomized controlled trials exist in OI children. This randomized controlled pilot study assesses the effect of 5 months WBVT (2 x 9min/day) on muscle function, mobility, bone structure and density. 24 children \>5 years with OI type 1 and 4 with limited mobility (CHAQ Score ≥0.13) will be randomized into a WBVT group and a control group matched by gender and pubertal stage. Main outcome measure is the change in tibial volumetric BMD, secondary outcomes include a variety of bone, mobility and dynamic muscle function variables.
AI analysis
Indication: Osteogenesis Imperfecta
Modality: RNA therapy
Target: Galileo M
Sponsor: Birmingham Women's and Children's NHS Foundation Trust
Source URL: ClinicalTrials.gov
Source updated: Jan 24, 2017
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Galileo M
Target normalized: Galileo M
NCT07164664Source recordAI-normalized
External Oblique Intercostal Block Versus Port-Site Infiltration for Postoperative Analgesia in Laparoscopic Cholecystectomy
Adequate postoperative pain management is essential for improving patient comfort and recovery after laparoscopic cholecystectomy. This study evaluated the effectiveness of the external oblique intercostal block compared with port-site infiltration in terms of pain scores and opioid consumption during the first 24 hours after surgery.
AI analysis
Indication: Pain, Postoperative
Modality: RNA therapy
Target: External Oblique Intercostal Block, Port-Site Infiltration, ıv morphine PCA
Sponsor: Ondokuz Mayıs University
Source URL: ClinicalTrials.gov
Source updated: Apr 09, 2026
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Pain, Postoperative, Pain, Acute, Opioid Use
Condition normalized: Pain, Postoperative, Pain, Acute, Opioid Use
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: External Oblique Intercostal Block, Port-Site Infiltration, ıv morphine PCA
Target normalized: External Oblique Intercostal Block, Port-Site Infiltration, ıv morphine PCA
NCT05534035Source recordAI-normalized
A Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were Previously Vaccinated With Vaxzevria®
This is a Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were Previously Vaccinated with Vaxzevria®. This study will be a competitive enrollment process in all participating countries. Once the target number of subjects is reached, the enrollment in all participating countries in the particular phase will be stopped.
AI analysis
Indication: SARS-CoV-2 Infection
Modality: RNA therapy
Target: PTX-COVID19-B, Vaxzevria®
Sponsor: Everest Medicines (Singapore) Pte. Ltd.
Source URL: ClinicalTrials.gov
Source updated: Sep 09, 2022
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: SARS-CoV-2 Infection
Condition normalized: SARS-CoV-2 Infection
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: PTX-COVID19-B, Vaxzevria®
Target normalized: PTX-COVID19-B, Vaxzevria®
NCT05534048Source recordAI-normalized
A Phase III Study to Evaluate the Safety and Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination in Previously Vaccinated Adults Aged 18 Years and Older
The purpose of this clinical trial is to Evaluate the Safety and Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination in Previously Vaccinated Adults Aged 18 Years and Older. This study is seeking participants who are: Adult males and females 18 years of age or older; In efficacy cohort : Subjects who were previously vaccinated with 2 doses of Comirnaty® administered at least 3 months prior to the booster dose.. All participants in this efficacy cohort will receive 1 of the 2 study vaccines: PTX-COVID19-B or Comirnaty®. All participants in efficacy cohort will receive a single 40 microgram dose PTX-COVID19-B of the study vaccine or one dose of Comirnaty® at the first study clinic and will return to the study clinic 6 more times. At each clinic visit, a blood sample will be taken. They study is about 6 months long for each participant. In safety cohort: Subjects who have previously received any primary series approved by WHO Emergency Use Authorization at least 3 months prior to enrollment or subjects who have already received one authorized booster vaccination and planned to receive PTX-COVID19-B as the 4th shot will be enrolled. All participants in this safety cohort will receive 1 dose vaccines: PTX-COVID19-B. All participants in safety cohort will receive a single 40 microgram dose of the study vaccine at the first study clinic and will return to the study clinic 5 more times. At each clinic visit, a blood sample will be taken. They study is about 6 months long for each participant.
AI analysis
Indication: SARS-CoV-2 Infection
Modality: RNA therapy
Target: PTX-COVID19-B, Comirnaty®
Sponsor: Everest Medicines (Singapore) Pte. Ltd.
Source URL: ClinicalTrials.gov
Source updated: Sep 09, 2022
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: SARS-CoV-2 Infection
Condition normalized: SARS-CoV-2 Infection
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: PTX-COVID19-B, Comirnaty®
Target normalized: PTX-COVID19-B, Comirnaty®
NCT06895018Source recordAI-normalized
Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects with Type 2 Diabetes
The study, sponsored by Federico II University, investigates the effects of a polyphenol-rich beverage derived from red grape pomace on non-alcoholic fatty liver disease (NAFLD) and related metabolic conditions in patients with type 2 diabetes. Given the rising prevalence of NAFLD and the absence of pharmacological treatments, this asset addresses a significant unmet medical need. The potential for dietary polyphenols to improve liver health and metabolic profiles could position this beverage favorably in the dietary supplement market, particularly among diabetic and obese populations. The competitive landscape includes other dietary interventions and emerging pharmacotherapies for NAFLD, necessitating a thorough market analysis and strategic positioning. Diligence should focus on regulatory pathways, especially concerning health claims and market entry strategies.
AI analysis
Indication: Diabetes Mellitus Type 2
Modality: RNA therapy
Target: Polyphenol metabolites and their phase II derivatives impacting hepatic steatosis, cardiometabolic risk, and gut microbiota composition.
Sponsor: Federico II University
Source URL: ClinicalTrials.gov
Source updated: Mar 26, 2025
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Diabetes Mellitus Type 2
Condition normalized: Diabetes Mellitus Type 2
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Polyphenol metabolites and their phase II derivatives impacting hepatic steatosis, cardiometabolic risk, and gut microbiota composition.
Target normalized: Polyphenol metabolites and their phase II derivatives impacting hepatic steatosis, cardiometabolic risk, and gut microbiota composition.
NCT01628367Source recordAI-normalized
The Effectiveness of the Cytoplast Technique in Preventing Bone Loss Around Immediate Implant Placement in the Esthetic Zone. A Randomized Clinical Trial.
An important result of healing after tooth extraction is a reduction in dimensions of the remaining bone at that site. This reduction of bone volume precludes successful restoration of the space using a dental implant. Bone augmentation has shown promise in clinical reports to reduce this loss of bone volume, thus allowing implant placement and restoration. The purpose of this study is to evaluate the clinical and radiographic outcomes of guided bone regeneration around dental implants placed in fresh extraction sockets.
AI analysis
Indication: Missing Tooth
Modality: RNA therapy
Target: Minimally Traumatic Tooth Extraction, Immediate Implant Placement, Bone Graft Placement, Membrane placement, Collagen plug placement, Medications
Sponsor: University of Michigan
Source URL: ClinicalTrials.gov
Source updated: Mar 20, 2017
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Missing Tooth
Condition normalized: Missing Tooth
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Minimally Traumatic Tooth Extraction, Immediate Implant Placement, Bone Graft Placement, Membrane placement, Collagen plug placement, Medications
Target normalized: Minimally Traumatic Tooth Extraction, Immediate Implant Placement, Bone Graft Placement, Membrane placement, Collagen plug placement, Medications
NCT04190004Source recordAI-normalized
Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia
This completed interventional study evaluated the effects of intranasal vasopressin on cooperative behavior in patients diagnosed with schizophrenia. The study involved a randomized, double-masked, crossover design with 30 participants, assessing behavioral performance in economic games.
AI analysis
Indication: Schizophrenia
Modality: RNA therapy
Target: Cooperative behavior in schizophrenia
Sponsor: National Institute of Mental Health and Neuro Sciences, India
Source URL: ClinicalTrials.gov
Source updated: Dec 09, 2019
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Schizophrenia
Condition normalized: Schizophrenia
Modality raw: Schizophrenia
Modality normalized: RNA therapy
Target raw: Cooperative behavior in schizophrenia
Target normalized: Cooperative behavior in schizophrenia
NCT05484804Source recordAI-normalized
Reducing Racial Disparities in Maternal Care Through Data-Based Accountability and Doula Support
The ACURE4Moms trial, led by the University of North Carolina, aims to address racial disparities in maternal health outcomes, particularly focusing on Black women. The study employs multi-level interventions, including data accountability and community-based doula support, across 39 prenatal practices in North Carolina. The trial is expected to enroll up to 60,000 patients and assess the effectiveness of these interventions on reducing low birthweight deliveries and experiences of discrimination during prenatal care.
AI analysis
Indication: Pregnancy Related
Modality: RNA therapy
Target: Reducing racial disparities in maternal care
Sponsor: University of North Carolina, Chapel Hill
Source URL: ClinicalTrials.gov
Source updated: Apr 17, 2026
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Pregnancy Related
Condition normalized: Pregnancy Related
Modality raw: Pregnancy Related
Modality normalized: RNA therapy
Target raw: Reducing racial disparities in maternal care
Target normalized: Reducing racial disparities in maternal care
NCT05985122Source recordAI-normalized
Towards the Most Accurate Diagnosis and Monitoring of Complement-mediated Rare Kidney Diseases
The COMPRare project aims to develop new diagnostic tools for aHUS and C3G, improving patient stratification and treatment monitoring. Funded by the EJP RD program of the EU, it involves a consortium of seven European institutions. The study focuses on identifying biomarkers and standardizing assays to enhance diagnosis and treatment options for these ultra-rare conditions.
AI analysis
Indication: Hemolytic-Uremic Syndrome
Modality: RNA therapy
Target: Complement-mediated Rare Kidney Diseases (aHUS and C3G)
Sponsor: Mario Negri Institute for Pharmacological Research
Source URL: ClinicalTrials.gov
Source updated: Mar 23, 2026
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Hemolytic-Uremic Syndrome
Condition normalized: Hemolytic-Uremic Syndrome
Modality raw: Hemolytic-Uremic Syndrome
Modality normalized: RNA therapy
Target raw: Complement-mediated Rare Kidney Diseases (aHUS and C3G)
Target normalized: Complement-mediated Rare Kidney Diseases (aHUS and C3G)
NCT03871491Source recordAI-normalized
Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial
The A-PLUS trial investigates the efficacy of a single oral dose of azithromycin in reducing maternal and neonatal deaths and infections during labor in low- and middle-income countries. Conducted by the NICHD Global Network, it aims to address significant public health issues related to maternal and neonatal mortality.
AI analysis
Indication: Maternal Death
Modality: RNA therapy
Target: Maternal and neonatal infections
Sponsor: NICHD Global Network for Women's and Children's Health
Source URL: ClinicalTrials.gov
Source updated: Oct 24, 2024
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Maternal Death
Condition normalized: Maternal Death
Modality raw: Maternal Death
Modality normalized: RNA therapy
Target raw: Maternal and neonatal infections
Target normalized: Maternal and neonatal infections
NCT04893928Source recordAI-normalized
Role of Information and Communication Technologies for Health Support in Inflammatory Bowel Diseases: The DAMASCO Trial (Stage I)
Role of Information and Communication Technologies for Health Support in Inflammatory Bowel Diseases: The DAMASCO Trial (Stage I) is a registry-stage clinical asset sponsored by Hospital Nacional Profesor Alejandro Posadas in Inflammatory Bowel Diseases, Knowledge, Attitudes, Practice, Quality of Life, Treatment Adherence and Compliance. SEO and diligence focus: QUECOMIICAT survey, Self-Efficacy for Appropriate Medication Use Scale, ICTs preferences and barriers survey, Focus group and IBD mobile App for health support (MAHS) development and validation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Inflammatory Bowel Diseases
Modality: RNA therapy
Target: QUECOMIICAT survey, Self-Efficacy for Appropriate Medication Use Scale, ICTs preferences and barriers survey, Focus group and IBD mobile App for health support (MAHS) development and validation
Sponsor: Hospital Nacional Profesor Alejandro Posadas
Source URL: ClinicalTrials.gov
Source updated: May 21, 2021
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: RNA therapy
View original source fields
Condition raw: Inflammatory Bowel Diseases
Condition normalized: Inflammatory Bowel Diseases
Modality raw: MASH
Modality normalized: RNA therapy
Target raw: QUECOMIICAT survey, Self-Efficacy for Appropriate Medication Use Scale, ICTs preferences and barriers survey, Focus group and IBD mobile App for health support (MAHS) development and validation
Target normalized: QUECOMIICAT survey, Self-Efficacy for Appropriate Medication Use Scale, ICTs preferences and barriers survey, Focus group and IBD mobile App for health support (MAHS) development and validation